纳武利尤单抗联合伊匹木单抗联合卡博替尼三药方案一线治疗晚期肾细胞癌:III期CheckMate 9ER试验已终止组的结果
III期CheckMate 9ER试验中纳武利尤单抗联合伊匹木单抗联合卡博替尼三药组因一线晚期肾细胞癌治疗格局变化而提前终止;本文报告终止前随机入组50例患者的探索性分析,中位随访39.1个月,盲态独立中心评估中位无进展生存期9.9个月、客观缓解率44.0%,3-4级治疗相关不良事件发生率84.0%。
要点
- 三药组50例初治晚期透明细胞肾细胞癌患者,中位随访39.1个月。
- 盲态独立中心评估中位无进展生存期9.9个月,中位总生存期37.0个月。
- 盲态独立中心评估客观缓解率44.0%,完全缓解率8.0%;3-4级治疗相关不良事件84.0%。
核心结论
- 结果提示纳武利尤单抗联合伊匹木单抗联合卡博替尼三药方案在初治晚期肾细胞癌患者中具有临床活性,但未来研究需重视重叠毒性的监测。
研究设计与样本
- III期CheckMate 9ER试验中因一线晚期肾细胞癌治疗格局变化而提前终止的三药组探索性分析,共50例透明细胞晚期肾细胞癌患者随机入组。
- 给药方案为纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg每3周一次共4个周期,同期每日一次卡博替尼40 mg,之后纳武利尤单抗240 mg每2周一次联合每日一次卡博替尼40 mg。
- 采用CheckMate 9ER主要终点(盲态独立中心评估的无进展生存期)和关键次要终点(总生存期、盲态独立中心评估的客观缓解率及安全性),并分析研究者评估的无进展生存期和客观缓解率。
主要发现
- 中位随访39.1个月(范围33.4-44.5)后,盲态独立中心评估的中位无进展生存期(95%CI)为9.9(5.7-16.8)个月,研究者评估为13.9(7.3-24.7)个月。
- 中位总生存期(95%CI)为37.0(31.8-不可估计)个月。
- 盲态独立中心评估的客观缓解率(95%CI)为44.0%(30.0-58.7),其中完全缓解率8.0%;研究者评估的客观缓解率(95%CI)为48.0%(33.7-62.6),均为部分缓解。
- 3-4级治疗相关不良事件发生率为84.0%,最常见为丙氨酸氨基转移酶升高(20.0%)、天冬氨酸氨基转移酶升高(16.0%)和肝毒性(16.0%)。
- 3-4级肝脏免疫介导不良事件发生率为40.0%,无5级治疗相关不良事件。
临床怎么用
- 作者认为该三药方案在初治晚期肾细胞癌中具有临床活性,并指出未来研究该方案时监测重叠毒性将很重要。
局限性
- 该三药组因一线晚期肾细胞癌治疗格局变化而提前终止入组,本文为终止前入组患者的探索性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase III CheckMate 9ER trial originally included a nivolumab plus ipilimumab plus cabozantinib triplet arm, which was discontinued early due to the evolving treatment landscape for first-line advanced renal cell carcinoma (aRCC). We report an exploratory analysis of patients randomised to the triplet regimen before enrolment discontinuation. METHODS: Patients with clear-cell aRCC received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) Q3W for four cycles with once-daily cabozantinib (40 mg), then nivolumab (240 mg) Q2W plus once-daily cabozantinib (40 mg). CheckMate 9ER primary (progression-free survival [PFS] by blinded independent central review [BICR]) and key secondary (overall survival [OS], objective response rate [ORR] by BICR, and safety) endpoints were applied, along with investigator-assessed PFS and ORR. RESULTS: Fifty patients were randomised to the triplet regimen. After a median follow-up of 39.1 months (range, 33.4-44.5), median PFS (95% CI) was 9.9 (5.7-16.8) months by BICR and 13.9 (7.3-24.7) months by investigator; median OS (95% CI) was 37.0 (31.8-not estimable) months. ORR (95% CI) was 44.0% (30.0-58.7; complete response, 8.0%) by BICR and 48.0% (33.7-62.6; all partial responses) by investigator. Grade 3-4 treatment-related adverse events (TRAEs) occurred in 84.0%, most commonly alanine aminotransferase increased (20.0%), aspartate aminotransferase increased (16.0%), and hepatotoxicity (16.0%). Grade 3-4 hepatic immune-mediated AEs occurred in 40.0%. There were no grade 5 TRAEs. CONCLUSIONS: These results suggest that the nivolumab plus ipilimumab plus cabozantinib triplet combination has clinical activity in patients with previously untreated aRCC, although monitoring of overlapping toxicities will be important in future studies of this regimen. CLINICALTRIALS: gov registration: NCT03141177.
引用
- Apolo AB, Powles T, Escudier B, et al. Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial. Eur J Cancer. 2022. PMID: 36327527. doi:10.1016/j.ejca.2022.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。